First Time Loading...

Guardant Health Inc
NASDAQ:GH

Watchlist Manager
Guardant Health Inc Logo
Guardant Health Inc
NASDAQ:GH
Watchlist
Price: 17.35 USD 1.11% Market Closed
Updated: Apr 27, 2024

Intrinsic Value

GH's intrinsic value estimate is unreliable because it is based only on its multiples and doesn't use a DCF valuation.

Guardant Health, Inc. is a precision oncology company, engages in treatment of cancer through use of proprietary blood-based tests, vast data sets, and advanced analytics. [ Read More ]

The intrinsic value of one GH stock under the Base Case scenario is 21.6 USD. Compared to the current market price of 17.35 USD, Guardant Health Inc is Undervalued by 20%.

Key Points:
GH Intrinsic Value
Base Case
21.6 USD
Undervaluation 20%
Intrinsic Value
Price
Worst Case
Base Case
Best Case

Valuation Backtest
Guardant Health Inc

Backtest Intrinsic Value
Dive into the past to invest in the future

Run backtest to discover the historical profit from buying and selling GH stocks based on their intrinsic value.

Analyze the historical link between intrinsic value and market price to make more informed investment decisions.

Run Backtest
Settings
Valuation Methods
Buy/Sell Thresholds
Buy When:
%
Sell When:
%
B
S
Run Backtest
How does it work?

Fundamental Analysis

Beta
Ask me anything about
Guardant Health Inc

Provide an overview of the primary business activities
of Guardant Health Inc.

What unique competitive advantages
does Guardant Health Inc hold over its rivals?

What risks and challenges
does Guardant Health Inc face in the near future?

Has there been any significant insider trading activity
in Guardant Health Inc recently?

Summarize the latest earnings call
of Guardant Health Inc.

Is it considered overvalued or undervalued
based on the latest financial data?

Show all valuation multiples
for Guardant Health Inc.

Provide P/S
for Guardant Health Inc.

Provide P/E
for Guardant Health Inc.

Provide P/OCF
for Guardant Health Inc.

Provide P/FCFE
for Guardant Health Inc.

Provide P/B
for Guardant Health Inc.

Provide EV/S
for Guardant Health Inc.

Provide EV/GP
for Guardant Health Inc.

Provide EV/EBITDA
for Guardant Health Inc.

Provide EV/EBIT
for Guardant Health Inc.

Provide EV/OCF
for Guardant Health Inc.

Provide EV/FCFF
for Guardant Health Inc.

Provide EV/IC
for Guardant Health Inc.

Show me price targets
for Guardant Health Inc made by professional analysts.

What are the Revenue projections
for Guardant Health Inc?

How accurate were the past Revenue estimates
for Guardant Health Inc?

What are the Net Income projections
for Guardant Health Inc?

How accurate were the past Net Income estimates
for Guardant Health Inc?

What are the EPS projections
for Guardant Health Inc?

How accurate were the past EPS estimates
for Guardant Health Inc?

What are the EBIT projections
for Guardant Health Inc?

How accurate were the past EBIT estimates
for Guardant Health Inc?

Compare the revenue forecasts
for Guardant Health Inc with those of its competitors based on recent analyst estimates.

Compare the intrinsic valuations
of Guardant Health Inc and its key competitors using the latest financial data.

Compare historical revenue growth rates
of Guardant Health Inc against its competitors.

Analyze the profit margins
(gross, operating, and net) of Guardant Health Inc compared to its peers.

Compare the P/E ratios
of Guardant Health Inc against its peers.

Discuss the investment returns and shareholder value creation
comparing Guardant Health Inc with its peers.

Analyze the financial leverage
of Guardant Health Inc compared to its main competitors.

Show all profitability ratios
for Guardant Health Inc.

Provide ROE
for Guardant Health Inc.

Provide ROA
for Guardant Health Inc.

Provide ROIC
for Guardant Health Inc.

Provide ROCE
for Guardant Health Inc.

Provide Gross Margin
for Guardant Health Inc.

Provide Operating Margin
for Guardant Health Inc.

Provide Net Margin
for Guardant Health Inc.

Provide FCF Margin
for Guardant Health Inc.

Show all solvency ratios
for Guardant Health Inc.

Provide D/E Ratio
for Guardant Health Inc.

Provide D/A Ratio
for Guardant Health Inc.

Provide Interest Coverage Ratio
for Guardant Health Inc.

Provide Altman Z-Score Ratio
for Guardant Health Inc.

Provide Quick Ratio
for Guardant Health Inc.

Provide Current Ratio
for Guardant Health Inc.

Provide Cash Ratio
for Guardant Health Inc.

What is the historical Revenue growth
over the last 5 years for Guardant Health Inc?

What is the historical Net Income growth
over the last 5 years for Guardant Health Inc?

What is the current Free Cash Flow
of Guardant Health Inc?

Discuss the annual earnings per share (EPS)
trend over the past five years for Guardant Health Inc.

Financials

Balance Sheet Decomposition
Guardant Health Inc

Current Assets 1.3B
Cash & Short-Term Investments 1.2B
Receivables 88.8m
Other Current Assets 89.7m
Non-Current Assets 439.3m
PP&E 302.7m
Intangibles 12.3m
Other Non-Current Assets 124.3m
Current Liabilities 205.9m
Accounts Payable 51.7m
Accrued Liabilities 136.2m
Other Current Liabilities 18m
Non-Current Liabilities 1.4B
Long-Term Debt 1.1B
Other Non-Current Liabilities 281.9m
Efficiency

Earnings Waterfall
Guardant Health Inc

Revenue
563.9m USD
Cost of Revenue
-227.1m USD
Gross Profit
336.9m USD
Operating Expenses
-901.6m USD
Operating Income
-564.7m USD
Other Expenses
85.3m USD
Net Income
-479.4m USD

Free Cash Flow Analysis
Guardant Health Inc

Last Value
3-Years Average
FCF Margin
Conversion Rate
History
Components
Chart
Table
Fundamental Scores

GH Profitability Score
Profitability Due Diligence

Guardant Health Inc's profitability score is 24/100. The higher the profitability score, the more profitable the company is.

Positive Gross Profit
Exceptional 3-Years Revenue Growth
Exceptional Revenue Growth Forecast
Exceptional 1-Year Revenue Growth
24/100
Profitability
Score

Guardant Health Inc's profitability score is 24/100. The higher the profitability score, the more profitable the company is.

GH Solvency Score
Solvency Due Diligence

Guardant Health Inc's solvency score is 42/100. The higher the solvency score, the more solvent the company is.

Short-Term Solvency
Negative Net Debt
Long-Term Solvency
High D/E
42/100
Solvency
Score

Guardant Health Inc's solvency score is 42/100. The higher the solvency score, the more solvent the company is.

Wall St
Price Targets

GH Price Targets Summary
Guardant Health Inc

Wall Street analysts forecast GH stock price to rise over the next 12 months.

According to Wall Street analysts, the average 1-year price target for GH is 39.84 USD with a low forecast of 27.27 USD and a high forecast of 56.7 USD.

Lowest
Price Target
27.27 USD
57% Upside
Average
Price Target
39.84 USD
130% Upside
Highest
Price Target
56.7 USD
227% Upside
View Analyst Estimates
View Analyst Estimates

Competitive Landscape

Ownership

GH Insider Trading
Buy and sell transactions by insiders

Cumulative Transactions Amount
Period Sold Bought Net
3 Months
6 Months
9 Months
12 Months
Why is insider trading important?

Shareholder Return

GH Price
Guardant Health Inc

1M 1M
-3%
6M 6M
-30%
1Y 1Y
-20%
3Y 3Y
-89%
5Y 5Y
-74%
10Y 10Y
-46%
Annual Price Range
17.35
52w Low
16.07
52w High
39.97
Price Metrics
Average Annual Return -3.49%
Standard Deviation of Annual Returns 56.97%
Max Drawdown -91%
Shares Statistics
Market Capitalization 2.1B USD
Shares Outstanding 121 713 000
Percentage of Shares Shorted 6.54%

GH Return Decomposition
Main factors of price return

What is price return decomposition?

GH News

Other Videos

Company Profile

Guardant Health Inc Logo
Guardant Health Inc

Country

United States of America

Industry

Health Care

Market Cap

2.1B USD

Dividend Yield

0%

Description

Guardant Health, Inc. is a precision oncology company, engages in treatment of cancer through use of proprietary blood-based tests, vast data sets, and advanced analytics. The company is headquartered in Redwood City, California and currently employs 1,373 full-time employees. The company went IPO on 2018-10-04. The firm is focused on helping conquer cancer through the use of its blood-based tests, data sets, and advanced analytics. The company has developed its Guardant360, Guardant360 CDx, and GuardantOMNI liquid biopsy-based tests for advanced-stage cancer. The company also developed its Guardant Reveal liquid biopsy-based test for residual and recurring cancer to address the need for Stage II-II I colorectal cancer. Its Guardant360 test is a molecular diagnostic test measuring 74 cancer-related genes. Its Guardant360 CDx test is a liquid biopsy test measuring 55 cancer-related genes. Its GuardantOMNI test has a broader 500-gene panel, all of which analyze circulating tumor deoxyribonucleic acid (DNA) in the blood. The firm's tests are used by biopharmaceutical companies for a range of applications, including identifying patient populations to accelerate translational science research and clinical trial enrollment, and companion diagnostic.

Contact

CALIFORNIA
Redwood City
505 Penobscot Dr
+18556988887.0
http://www.guardanthealth.com

IPO

2018-10-04

Employees

1 373

Officers

Co-Founder, Co-CEO & Chairman
Dr. Helmy Eltoukhy Ph.D.
Co-CEO & Director
Dr. AmirAli Talasaz Ph.D.
Chief Financial Officer
Mr. Michael Bell
Chief Legal Officer & Corporate Secretary
Mr. John G. Saia
Chief Medical Officer
Dr. Craig Eagle M.D.
Chief Commercial Officer
Mr. Christopher Freeman
Show More
Chief Technology Officer
Ms. Darya Chudova
Chief Information Officer
Mr. Kumud Kalia
Vice President of Public Affairs
Ms. Jennifer Higgins
Chief People Officer
Ms. Terilyn Juarez Monroe
Show Less

See Also

Discover More
What is the Intrinsic Value of one GH stock?

The intrinsic value of one GH stock under the Base Case scenario is 21.6 USD.

Is GH stock undervalued or overvalued?

Compared to the current market price of 17.35 USD, Guardant Health Inc is Undervalued by 20%.